Malignancy: Clinical Trials

5 trials for Malignancy, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 recruiting. 5 Phase 2, 3 Phase 3, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 25Recruiting 5
Phase 33Recruiting 3
Phase 11Recruiting 1

Follow Malignancy: new trials by email Literature Review of Malignancy trials Research Report on Malignancy

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.
Entrectinib - Haematological Malignancy, Malignancy
Phase 2 / Phase 3RecruitingCancer Research UK302025-11-302025-11-24
Evaluating Informatics-assisted Immune-related Adverse Event Detection to Improve Registration Onto a Biorepository
Informatics system for eligibility monitoring, Standard eligibility monitoring - Malignancy, Immune Related Adverse Events
Phase 1 / Phase 2RecruitingBrigham and Women's Hospital1002025-06-172025-06-19
DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations
Capmatinib - Solid Tumour, Haematological Malignancy
Phase 2 / Phase 3RecruitingCancer Research UK302024-11-192025-11-24
DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
Atezolizumab - Malignancy, Malignant Neoplasm
Phase 2 / Phase 3RecruitingCancer Research UK302023-10-252025-11-24
Application of 18F-PSMA PET / CT Imaging in Prostate Specific Membrane Antigen Positive Tumor
Al18F-PSMA-BCH PET/CT - Malignancy
Phase 2RecruitingCancer Institute and Hospital, Chinese Academy of Medical Sciences4002022-10-132024-12-27

Narrower conditions

Neoplasms (5)  ·  Neoplasms by Histologic Type (3)  ·  Neoplasms by Site (3)  ·  Glioma (2)  ·  Hematologic Neoplasms (2)  ·  Lymphoproliferative Disorders (2)  ·  Melanoma (2)  ·  Brain Neoplasms (1)  ·  Colorectal Neoplasms (1)  ·  Drug-Related Side Effects and Adverse Reactions (1)  ·  Endometrial Neoplasms (1)  ·  Neuroblastoma (1)  ·  Sarcoma (1)  ·  Stomach Neoplasms (1)

Broader conditions

Hemic and Lymphatic Diseases (3)  ·  Neoplasms, Germ Cell and Embryonal (3)  ·  Neoplasms, Nerve Tissue (3)  ·  Neuroectodermal Tumors (3)  ·  Digestive System Diseases (2)  ·  Digestive System Neoplasms (2)  ·  Gastrointestinal Diseases (2)  ·  Gastrointestinal Neoplasms (2)  ·  Hematologic Diseases (2)  ·  Immune System Diseases (2)  ·  Immunoproliferative Disorders (2)  ·  Lymphatic Diseases (2)  ·  Neoplasms, Glandular and Epithelial (2)  ·  Neoplasms, Neuroepithelial (2)  ·  Neuroendocrine Tumors (2)

Interventions

atezolizumab (1)  ·  capmatinib (1)  ·  entrectinib (1)

Sponsors

Cancer Research UK (3)  ·  Brigham and Women's Hospital (1)  ·  Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1)

Countries

United Kingdom (3)  ·  China (1)  ·  United States (1)

Top investigators

Matthew Krebs, Dr (3)  ·  Rong Zheng, MD (1)

Results publications

PMID 38662981

NIH funding

R01CA294033 (1)